Prestige Consumer Healthcare Inc

The breakdown below the $50.60–$49.70 support zone on elevated volume under Stage 4 decline confirms a medium-term bearish bias. Price sits below the 9/21 EMAs and 50 SMA in an extended downtrend into extreme oversold territory. With no stabilizing reversal structures, selling into any rally toward the broken support or EMAs is advised immediately.

• ↑Q1 revenue $266M (+6.5% YoY) and record $83.7M free cash flow
• ↑Breathe Right and Lacorium acquisitions to add ~$190M revenue this year
• ↓Full-year revenue fell 4.5% YoY, driven by eye care supply issues